Form 4: Cartesian Therapeutics Chief Scientific Officer Exercises Stock Options
SEC Form 4 Filing
Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, exercised stock options for 14,000 shares of common stock at $3.23 per share.
Summary
- Christopher M. Jewell, the Chief Scientific Officer of Cartesian Therapeutics, exercised stock options to acquire 14,000 shares of common stock.
- The transaction occurred on November 20, 2024, at a price of $3.23 per share.
- Following this transaction, Mr. Jewell directly owns 39,940 shares of common stock.
- The exercised options were part of a larger option grant that is currently exercisable for 123,235 shares and will be fully exercisable by June 16, 2025.
- These options were originally granted for shares of Old Cartesian and converted to options for the Issuer's Series A Preferred Stock during a merger on November 13, 2023, and then converted to common stock on April 8, 2024.
Sentiment
Score: 6
Explanation: The document is neutral in sentiment, as it reports a routine stock option exercise. It doesn't indicate any positive or negative news about the company's performance.
Positives
- The exercise of options by a key executive could indicate confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider transactions.
- The exercise of stock options by executives is a common form of compensation and is not unusual in the biotech industry.
- The specific details of the option grants and vesting schedules are unique to Cartesian Therapeutics and its compensation policies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it increases the number of shares outstanding, but the impact is likely negligible given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 11/13/2023 | Cartesian Therapeutics acquired Old Cartesian in a merger, converting Old Cartesian stock options to options for the Issuer's Series A Preferred Stock. |
| 04/08/2024 | Options previously exercisable for Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock. |
| 11/20/2024 | Christopher M. Jewell exercised stock options for 14,000 shares of common stock. |
| 11/21/2024 | Form 4 filing date. |
| 06/16/2025 | Date when the stock options will be fully exercisable. |
| 01/15/2033 | Expiration date of the stock options. |
Keywords
stock options, insider trading, common stock, Cartesian Therapeutics, executive compensation, Form 4, RNAC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.